CN114544822A - Application of reagent for detecting lysophosphatidylcholine (22:0) in plasma in preparation of depression detection kit - Google Patents
Application of reagent for detecting lysophosphatidylcholine (22:0) in plasma in preparation of depression detection kit Download PDFInfo
- Publication number
- CN114544822A CN114544822A CN202011334992.3A CN202011334992A CN114544822A CN 114544822 A CN114544822 A CN 114544822A CN 202011334992 A CN202011334992 A CN 202011334992A CN 114544822 A CN114544822 A CN 114544822A
- Authority
- CN
- China
- Prior art keywords
- depression
- lysophosphatidylcholine
- kit
- plasma
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UIINDYGXBHJQHX-GDLZYMKVSA-N 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C UIINDYGXBHJQHX-GDLZYMKVSA-N 0.000 title claims abstract description 28
- 238000001514 detection method Methods 0.000 title claims abstract description 21
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 12
- 235000019253 formic acid Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 5
- 238000004811 liquid chromatography Methods 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 abstract description 23
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 239000003550 marker Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
Abstract
The invention discloses application of a reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of a depression detection kit, and belongs to the field of depression detection. The application of the invention is based on the difference of lysophosphatidylcholine (22:0) in the plasma of a depression patient and a normal person, and the difference is enough to accurately distinguish the depression patient from the normal person. The invention also discloses a detection kit based on the principle. The kit can realize quantifiable objective detection and has the advantages of sensitivity, rapidness and high reliability.
Description
Technical Field
The invention belongs to the field of depression detection, and particularly relates to application of a reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of a depression detection kit.
Background
Depression is a major type of mood disorder, with significant and persistent mood swings as the primary clinical feature. As one of the diseases with the highest disability rate in the world, the burden on families, healthcare systems and society by depression patients is enormous. It is estimated that depression symptoms are present in up to 50% of 80 million suicide worldwide per year. At present, the total number of depression patients in the world is more than 3.5 hundred million people, and more than 5400 million people in China have depression.
The depression has obvious heredity, the heredity rate reaches 30-40 percent, and a plurality of genetic factors are involved. It is also affected by a number of non-genetic factors which increase the complexity of the pathogenesis of depression. The unclear pathogenesis causes that the diagnosis method for the disease always stays in subjective observation layers such as questionnaire scales and the like, lacks objective examination indexes, and has high operation difficulty and long diagnosis period. Therefore, it is urgent to develop a diagnostic method or apparatus based on objective indicators that can be quantified, which is sensitive, fast, and highly reliable.
Lysophosphatidylcholine (LPC) is an intermediate product of lecithin metabolism in vivo and, if present at elevated concentrations, lyses the red cell membrane. Under the catalysis of lecithin cholesterol acyltransferase, lecithin in plasma can be changed into lysolecithin. Lysophosphatidylcholine (22:0) is one of the lysophosphatidylcholines. At present, no relation between lysophosphatidylcholine (22:0) in blood and depression has been reported.
Disclosure of Invention
The invention aims to solve the problems that: provided is a novel use of lysophosphatidylcholine (22:0) as a marker for depression.
The technical scheme of the invention is as follows:
use of a reagent for detecting lysophosphatidylcholine (22:0) in plasma in the preparation of a depression detection kit.
Further, the reagent is used for a liquid chromatography-mass spectrometry combined method.
Further, the reagent is a reagent for a liquid chromatography method.
Further, the kit comprises T3HSS column, 0.1% formic acid dissolved in pure water as mobile phase a and 0.1% formic acid dissolved in acetonitrile as mobile phase B.
Further, the detection standard of the kit is as follows: when the plasma lysophosphatidylcholine (22:0) of the tested person is obviously lower than that of the healthy people, the person with high risk of depression is judged.
A depression detection kit, characterized in that: the kit comprises a reagent for detecting lysophosphatidylcholine (22:0) in plasma.
Further, the reagent is used for a liquid chromatography-mass spectrometry combined method.
Further, the reagent is a reagent for a liquid chromatography method.
Further, the kit comprises T3HSS column, 0.1% formic acid dissolved in pure water as mobile phase a and 0.1% formic acid dissolved in acetonitrile as mobile phase B.
Further, the detection standard of the kit is as follows: when the plasma lysophosphatidylcholine (22:0) of the tested person is obviously lower than that of the healthy people, the person with high risk of depression is judged.
The key point of the invention is that the level of human plasma lysophosphatidylcholine (22:0) is determined to be significantly related to depression, so that the risk of suffering from depression can be judged by detecting the level of human plasma lysophosphatidylcholine (22:0), and the specific means for detecting the lysophosphatidylcholine (22:0) can be any of various means disclosed in the prior art, and the liquid chromatography-mass spectrometry combined method is adopted for detection in the embodiment of the invention, but the method is not limited to the method.
The invention provides a novel depression detection marker and a novel depression detection kit, which can realize quantifiable objective detection of depression and have the advantages of sensitivity, rapidness and high reliability.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1: relative amounts of lysophosphatidylcholine (22:0) in depression and normal control plasma; CON, control; MDD, depression.
Detailed Description
Example 1 Depression detection kit and method of use thereof
1. Composition of the kit
Standard pure solution containing 12mg/ml plasma metabolism marker, 1 root C8BEH column (1.7 μm, 2.1X 100mm) and 1T3HSS column (1.8 μm, 2.1X 100mm), 0.1% formic acid dissolved in pure water, 0.1% formic acid dissolved in acetonitrile. Wherein the plasma metabolism marker is lysophosphatidylcholine (22: 0).
2. Method of use
(a) Injecting the prepared plasma sample into a chromatographic column through an autosampler to separate metabolites respectively in a positive ionization mode and a negative ionization mode, wherein the specific chromatographic conditions are as follows: the mobile phase A is 0.1 percent formic acid dissolved in pure water; mobile phase B was acetonitrile-dissolved 0.1% formic acid. For positive mode, the gradient starts initially at 10% B, increases linearly to 40% B in 4 minutes after 1 minute, then increases to 100% B in 12 minutes and maintains for 5 minutes, then returns to the initial ratio equilibrium for about 3 minutes. In negative mode, the gradient starts at 100% a, increases linearly to 40% B after 1 minute, then increases to 100% B in 9 minutes, and remains for 4 minutes, then returns to the initial ratio equilibrium for about 4 minutes. The column temperature was 55 ℃.
(b) The separated metabolites were introduced into a liquid chromatography-mass spectrometer Shimadzu LC (30AD) -MS (TQ 8050) to obtain dynamic Multiple Reaction Monitoring (MRM) data for validation, the main parameters of the mass spectrum were the same as positive and negative modes: the flow rate of the heating gas is 10L/min; the flow rate of the dry gas flow is 10L/min; the flow rate of the atomization airflow is 3L/min; the DL temperature is 250 ℃; the temperature of the heating block is 400 ℃; the interface heater temperature was 300 ℃.
(c) Assessing whether the subject has depression based on the relative concentration of lysophosphatidylcholine (22: 0). A relative concentration of < 0.0027 is considered to be a high risk of having depression.
The kit is designed based on the plasma metabolism marker provided by the invention, and can be used for accurately diagnosing and accurately evaluating depression patients.
To demonstrate the effectiveness of lysophosphatidylcholine (22:0) in evaluating depression, the present application provides the following experimental examples.
Experimental example 1 comparison of plasma lysophosphatidylcholine (22:0) concentration between Depression patients and Normal controls
50 clinically diagnosed depression and normal controls were collected separately, and 5ml plasma samples were prepared for each collection. 100 samples were obtained from the first hospital affiliated with Chongqing medical university, and subjects in the depression group were excluded from past or present suffering from other neurological or psychiatric disorders, alcoholism or dependence on illicit drug use or pregnancy and were diagnosed as depression by the first hospital affiliated with Chongqing medical university using the DSM-IV-TR criteria and conducted the Hamilton Depression Scale to assess the severity of depression. The normal control group subjects exclude any past or present neurological disease, I or II axis disease or systemic medical disease. The study protocol fully met the ethical standards of human trials and was approved by the ethical committee of the university of Chongqing medical, with subjects informed prior to the trial and informed written consent.
The plasma sample was tested for plasma lysophosphatidylcholine (22:0) concentration by the kit and method of example 1, and the results are shown in FIG. 1, where the plasma lysophosphatidylcholine (22:0) concentration in patients with depression was much lower than that in the control (p)<0.001) FDR of 0.0001，Log2|FC|＝-0.9965。
Note: FDR refers to the false discovery rate, with an FDR of 0 indicating an expected value of 0.0001 for the number of false rejects (rejecting true (original) hypotheses) as a proportion of the number of all rejected original hypotheses. (ii) a FC refers to fold change.
The results of the experimental examples show that plasma lysophosphatidylcholine (22:0) is significantly lower in patients with depression than in normal persons, and the plasma lysophosphatidylcholine (22:0) concentration can be used to distinguish patients with depression from normal persons.
In conclusion, the kit can be used for rapid auxiliary diagnosis of depression and has good application prospect.
Claims (10)
1. Use of a reagent for detecting lysophosphatidylcholine (22:0) in plasma in the preparation of a depression detection kit.
2. Use according to claim 1, characterized in that: the reagent is used in a liquid chromatography-mass spectrometry method.
3. Use according to claim 1, characterized in that: the reagent is used for a liquid chromatography method.
4. Use according to claim 2 or 3, characterized in that: the kit comprises T3HSS column, 0.1% formic acid dissolved in pure water as mobile phase a and 0.1% formic acid dissolved in acetonitrile as mobile phase B.
5. Use according to claim 1, characterized in that: the detection standard of the kit is as follows: when the plasma of the tested person has lysophosphatidylcholine (22:0) which is obviously lower than that of the healthy people, the person is judged to be a person with high risk of depression.
6. A depression detection kit, characterized in that: the kit comprises a reagent for detecting lysophosphatidylcholine (22:0) in plasma.
7. The kit of claim 6, wherein: the reagent is used in a liquid chromatography-mass spectrometry combined method.
8. The kit of claim 6, wherein: the reagent is used for a liquid chromatography method.
9. The kit of claim 7 or 8, wherein: the kit comprises T3HSS column, 0.1% formic acid dissolved in pure water as mobile phase a and 0.1% formic acid dissolved in acetonitrile as mobile phase B.
10. The kit of claim 6, wherein: the detection standard of the kit is as follows: when the plasma of the tested person has lysophosphatidylcholine (22:0) which is obviously lower than that of the healthy people, the person is judged to be a person with high risk of depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011334992.3A CN114544822B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011334992.3A CN114544822B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114544822A true CN114544822A (en) | 2022-05-27 |
| CN114544822B CN114544822B (en) | 2023-10-24 |
Family
ID=81659213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011334992.3A Active CN114544822B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114544822B (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090305323A1 (en) * | 2005-10-24 | 2009-12-10 | Kaddurah-Daouk Rima F | Lipidomics approaches for central nervous system disorders |
| CN102565267A (en) * | 2012-01-06 | 2012-07-11 | 北京师范大学 | Kit for screening colorectal cancer |
| CN102788883A (en) * | 2012-08-30 | 2012-11-21 | 重庆医科大学 | Kit for detecting depression |
| WO2014150329A1 (en) * | 2013-03-14 | 2014-09-25 | University Of Georgia Research Foundation, Inc. | Lipid biomarkers of addiction and relapse risk |
| JP2016045112A (en) * | 2014-08-25 | 2016-04-04 | 株式会社 レオロジー機能食品研究所 | Ether phospholipid quantifying method |
| US20170151287A1 (en) * | 2015-11-30 | 2017-06-01 | Flagship Ventures Management, Inc. | Methods and compositions of chondrisomes |
| US20180024132A1 (en) * | 2016-07-07 | 2018-01-25 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
| CN108885219A (en) * | 2016-02-04 | 2018-11-23 | 梅坦诺米克斯有限公司 | Device and method for identifying heart failure and pulmonary disease in subject |
| CN109164194A (en) * | 2018-11-02 | 2019-01-08 | 质谱生物科技有限公司 | The detection method and its kit of lysophosphatidyl cholines in dried blood spot |
| US20190008873A1 (en) * | 2015-06-18 | 2019-01-10 | Sage Therapeutics, Inc. | Neuroactive steroid solutions and their methods of use |
| CN109444433A (en) * | 2018-12-18 | 2019-03-08 | 深圳先进技术研究院 | D-Ser is preparing application and Diagnosis of Depression kit in Diagnosis of Depression kit as marker |
| CN110286191A (en) * | 2019-06-27 | 2019-09-27 | 山西大学 | Metabolic indicator object detecting method and application in a kind of biological sample |
-
2020
- 2020-11-24 CN CN202011334992.3A patent/CN114544822B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090305323A1 (en) * | 2005-10-24 | 2009-12-10 | Kaddurah-Daouk Rima F | Lipidomics approaches for central nervous system disorders |
| CN102565267A (en) * | 2012-01-06 | 2012-07-11 | 北京师范大学 | Kit for screening colorectal cancer |
| CN102788883A (en) * | 2012-08-30 | 2012-11-21 | 重庆医科大学 | Kit for detecting depression |
| WO2014150329A1 (en) * | 2013-03-14 | 2014-09-25 | University Of Georgia Research Foundation, Inc. | Lipid biomarkers of addiction and relapse risk |
| JP2016045112A (en) * | 2014-08-25 | 2016-04-04 | 株式会社 レオロジー機能食品研究所 | Ether phospholipid quantifying method |
| US20190008873A1 (en) * | 2015-06-18 | 2019-01-10 | Sage Therapeutics, Inc. | Neuroactive steroid solutions and their methods of use |
| US20170151287A1 (en) * | 2015-11-30 | 2017-06-01 | Flagship Ventures Management, Inc. | Methods and compositions of chondrisomes |
| CN108885219A (en) * | 2016-02-04 | 2018-11-23 | 梅坦诺米克斯有限公司 | Device and method for identifying heart failure and pulmonary disease in subject |
| US20180024132A1 (en) * | 2016-07-07 | 2018-01-25 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
| CN109164194A (en) * | 2018-11-02 | 2019-01-08 | 质谱生物科技有限公司 | The detection method and its kit of lysophosphatidyl cholines in dried blood spot |
| CN109444433A (en) * | 2018-12-18 | 2019-03-08 | 深圳先进技术研究院 | D-Ser is preparing application and Diagnosis of Depression kit in Diagnosis of Depression kit as marker |
| CN110286191A (en) * | 2019-06-27 | 2019-09-27 | 山西大学 | Metabolic indicator object detecting method and application in a kind of biological sample |
Non-Patent Citations (6)
| Title |
|---|
| DUDZIK, D ET AL: ""Metabolic fingerprint of Gestational Diabetes Mellitus"", 《JOURNAL OF PROTEOMICS》, vol. 103, pages 57 - 71 * |
| LIU XY. ET AL: ""Discovery and Validation of Plasma Biomarkers for Major Depressive Disorder Classification Based on Liquid Chromatography−Mass Spectrometry"", 《JOURNAL OF PROTEOME RESEARCH》, vol. 14, no. 5, pages 2322 - 2330, XP055916861, DOI: 10.1021/acs.jproteome.5b00144 * |
| LIU, XY ET AL: ""Plasma lipidomics reveals potential lipid markers of major depressive disorder"", 《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》, vol. 408, no. 23, pages 6497 - 6507, XP036046107, DOI: 10.1007/s00216-016-9768-5 * |
| 刘职瑞等: ""基于代谢组学的百合知母汤治疗抑郁症的作用研究"", 《第三军医大学学报》, vol. 41, no. 20, pages 1917 - 1925 * |
| 祖先鹏: ""抑郁症患者代谢组与肠道菌群结构特征分析及Bacopaside Ⅰ抗抑郁作用的机制研究"", 《中国优秀博士学位论文全文数据库医药卫生科技》, no. 1, pages 1 - 244 * |
| 赵明亮等: ""高原缺氧代谢组学研究进展"", 《中草药》, vol. 49, no. 4, pages 948 - 954 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114544822B (en) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106979982B (en) | Method and kit for diabetes risk prediction and treatment evaluation | |
| JP6021187B2 (en) | Metabolic biomarkers of autism | |
| WO2022206264A1 (en) | Method for diagnosing and treating white matter lesion and application | |
| US20180088126A1 (en) | Method of identifying proteins in human serum indicative of pathologies of human lung tissues | |
| Anada et al. | Panel of serum protein biomarkers to grade the severity of traumatic brain injury | |
| JP2014521928A (en) | Method for diagnosing an increased risk of Alzheimer's disease | |
| CN113624868A (en) | Biomarker combination for predicting or evaluating cognitive function of bipolar affective disorder patient and application thereof | |
| CN114544790B (en) | Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit | |
| CN114544822B (en) | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit | |
| CN114544825A (en) | Application of reagent for detecting lysophosphatidylcholine (16:1) in plasma in preparation of depression detection kit | |
| CN114544821B (en) | Application of reagent for detecting phosphatidylethanolamine (36:4) in blood plasma in preparation of depression detection kit | |
| CN114544826B (en) | Application of reagent for detecting histidine in blood plasma in preparation of depression detection kit | |
| EP3707513B1 (en) | Method for establishing the presence and progression of neurodegenerative disease | |
| CN113552228A (en) | Combined markers for diagnosing childhood bronchiolitis and application and detection kit thereof | |
| CN114026427A (en) | Marker for diagnosing renal disease and diagnostic method | |
| CN111751457A (en) | Gouty arthritis diagnosis kit and application thereof | |
| RU2818128C2 (en) | Method for diagnosing mental disorders by blood lipids | |
| WO2009026153A1 (en) | Biomarkers for alzheimer's disease and methods using the same | |
| Peng et al. | Investigating HMGB1 as a potential serum biomarker for early diabetic nephropathy monitoring by quantitative proteomics | |
| CN113624870A (en) | Biomarker combination for predicting PANSS scale score of schizophrenia patient and application thereof | |
| CN113624865A (en) | Biomarker combination for predicting or evaluating cognitive function of depression patient and application thereof | |
| CN117110493A (en) | Metabolic marker associated with neonatal pneumonia and metabolic acidosis and application thereof | |
| CN114047263A (en) | Application of metabolic marker in preparation of detection reagent or detection object for diagnosing AIS (automatic identification system) and kit | |
| WO2023285462A1 (en) | Biomarkers for alzheimer's disease | |
| WO2022249182A2 (en) | Diagnosis of autism spectrum disorder by multiomics platform |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |